Home / Market News / $INO
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Jefferies Maintains Inovio Pharmaceuticals at Buy, Raises Price Target to $8

Nov 7, 2026, 2:07 PM UTC · Primary ticker $INO

Jefferies has maintained its 'Buy' rating on Inovio Pharmaceuticals and significantly raised its price target from $3 to $8. This indicates strong analyst confidence in the company's future prospects and development pipeline, suggesting potential upside for the stock.

Investment firm Jefferies maintained its 'Buy' rating on Inovio Pharmaceuticals and substantially increased its price target from $3 to $8. This analyst action reflects continued confidence in Inovio's strategic direction and development pipeline, implying significant upside potential for the stock. For traders, this could signal a positive short-term catalyst, potentially attracting new investors and driving up demand. Long-term implications depend on the company's ability to execute on its pipeline and meet these elevated expectations. A key opportunity for traders is to capitalize on the potential upward momentum following this positive analyst coverage.

$INO positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.